Biovie Inc. (BIVI) is a progressive American biopharmaceutical company devoted to the discovery, development, and commercialization of innovative drug therapies focused primarily on liver-related diseases. With the head office based in Beverly, Massachusetts, Biovie Inc. conducts its work with an unwavering commitment to improving patient care with products that address critical and unmet medical needs.
Biovie Inc. came into existence to bring solutions to common problems associated with liver-related diseases, such as ascites - the most common complication of advanced liver cirrhosis. This condition affects around half of the patients with liver cirrhosis within a decade of diagnosis, presenting significant physical discomfort and substantial risks owing to complications like spontaneous bacterial peritonitis and hepato-renal syndrome.
To combat this difficult health problem, Biovie Inc. is pioneering the development of a potential breakthrough treatment, BIV201 (continuous infusion terlipressin), which could become the first FDA-approved drug for treating ascites in over twenty years, assuming successful completion of clinical trials.
In pre-clinical and early-phase 1 and 2 clinical trials, BIV201 has shown promise in reducing excess fluid accumulation and complications associated with ascites. Notably, this therapy has the potential to provide better outcomes compared to current treatments, reduce hospitalizations, and improve patients' quality of life significantly.
The management team comprising experienced professionals leads Biovie Inc., relentlessly focused on advancing its drug pipeline and enhancing shareholder value. The company is publicly listed on OTC Markets under the symbol BIVI.
Furthermore, Biovie Inc. consistently strives to act responsibly, honoring its commitment to patients, healthcare partners, stakeholders, and the environments in which it operates. Biovie firmly believes that these practices are essential for sustainable business operations, and integrates them into its decision-making approach.
In conclusion, Biovie Inc. stands out as a passionate and innovative company, dedicated to the development of groundbreaking therapies for liver-related diseases. Its continued pursuit of excellence underscores its commitment to improve patient health and quality of life dramatically, hopefully bringing solace to thousands of patients across the globe suffering from ascites and other liver-related diseases. Its ongoing clinical trials promise a hopeful future for those affected and indeed for the field of pharmaceuticals as a whole.